Company Overview - Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, founded in 2007 and headquartered in Cambridge, Massachusetts [4]. Financial Results Announcement - Akebia plans to release its financial results for the fourth quarter and full year ended December 31, 2024, on March 13, 2025, prior to the opening of financial markets [1]. Conference Call Details - A conference call will be held on March 13, 2024, at 8:00 a.m. ET to discuss the financial results and recent business highlights, with registration required for access [2]. - A live webcast of the conference call will be available on Akebia's website, along with an online archive of the webcast [3].

Akebia Therapeutics (NASDAQ: AKBA ) is currently working on kidney-related diseases, mostly by using its HIF platform. As it stands now, AKBA is transitioning from relying on Auryxia to Vafseo, which is probably the biggest risk it faces today. Nevertheless, Vafseo is seeing some early successes soMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio Univer ...

Core Points - Akebia Therapeutics, Inc. granted options to purchase 130,763 shares of common stock to seven newly-hired employees as an inducement for employment [1][2] - The exercise price of the options is set at $2.24 per share, matching the closing price on the grant date [2] - The stock options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly, contingent on continued service [2] Company Overview - Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, founded in 2007 and headquartered in Cambridge, Massachusetts [3]

New Commercial Supply Contracts for Vafseo® (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S. Vafseo tablets now shipping in the U.S. Plan to start Phase 3 trial in mid-2025 to potentially expand Vafseo label to include treatment of late-stage non-dialysis CKD patients Company to discuss business updates at 43rd Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., Jan. 13, 2025 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Akebia Therapeutics, Inc. (AKBA) is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 26.3% downward over the last 60 days.Coca-Cola FEMSA, S.A.B. de C.V. (KOF) is a franchise bottler company. The Zacks Consensus Estimate for its current year earnings has been revised 10.5% downward over the last 60 days.DENTSPLY SIRONA Inc. (XRAY) is a dental products company.The Zacks Consensus ...

Company Overview - Akebia Therapeutics, Inc. is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease [3] - The company was founded in 2007 and is headquartered in Cambridge, Massachusetts [3] Upcoming Event - John Butler, the Chief Executive Officer of Akebia, will participate in a Fireside Discussion at the 36th Annual Piper Sandler Healthcare Conference on December 3, 2024, at 10:30 AM EST [1] - The Piper Sandler Healthcare Conference will be held from December 3-5, 2024, in New York [3] Webcast Information - A webcast of the presentation will be available in the "Investors" section of Akebia's website for six months following the conference [2]

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:ATI Inc. (ATI) is a specialty manufacturing company. The Zacks Consensus Estimate for its current year earnings has been revised 5.2% downward over the last 60 days.Akebia Therapeutics, Inc. (AKBA) is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 26.3% downward over the last 60 days.Alta Equipment Group Inc. (ALTG) is an equipment dealership company. The Zacks Consensus Estima ...

Chris Lau is an individual investor and economist with 30 years of experience covering life science, technology, and dividend-growth income stocks. He has degrees in Microbiology and Economics. Chris runs the investing group DIY Value Investing where he shares his top stock picks of undervalued stocks with catalysts for upside, dividend-income recommendations with quant and payment calendar tracking, high upside plays, and research requests to help you become a better do-it-yourself investor. Learn more. To ...

Akebia continues to publish important results of FO2CUS trial to further physicians' understanding of Vafseo® (vadadustat) CAMBRIDGE, Mass., Nov. 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the American Journal of Kidney Disease has published the results of FO2CUS, an open-label study evaluating the efficacy and safety of vadadustat, an oral hypoxia-inducible fa ...

Group 1 - Akebia Therapeutics, Inc. is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease [1][2] - The company will have its CEO, John Butler, present at the Jefferies London Healthcare Conference on November 21, 2024, at 1:00 PM GMT [1] - A webcast of the presentation will be available for 30 days on Akebia's website [1] Group 2 - The Jefferies London Healthcare Conference is scheduled to take place from November 19-21, 2024, in London [2] - Akebia Therapeutics was founded in 2007 and is headquartered in Cambridge, Massachusetts [2]